EnzelsbergerHMetkaMHeytmanekGSchurzBKurzCKusztrichM. Influence of oral contraceptive use on bone density in climacteric women. Maturitas1988; 9: 375–8.
2.
ThorneycroftIH. The role of estrogen replacement therapy in the prevention of osteoporosis. Am J Obstet Gynecol1989; 160: 1306–10.
3.
KatzungBG. Basic and clinical pharmacology. 4th ed.Norwalk, CT: Appleton and Lance, 1989: 439–506.
4.
EttingerB. Prevention of osteoporosis: Treatment of estradiol deficiency. Obstet Gynecol1988; 72 (suppl):12S–6S.
5.
ChristiansenCChristensenMSTransbolIB. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet1981; 1: 459–61.
6.
LindsayRHartDMClarkDM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol1984; 63: 759–63.
7.
ShargilAA. Hormone replacement therapy in perimenopausal women with triphasic contraceptive compound: A three year prospective study. Int J Fertil1985; 30: 15–28.
8.
CoeFLParksJH. The risks of oral contraceptives and estrogen replacement therapy. Persp Biol Med1989; 33: 86–106.
9.
GriffithRSBlackHR. Erythromycin. Med Clin North Am1970; 54: 1199–215.
10.
StrausbaughLJBoltonWKDilworthJAGuerrantRLSandeMA. Comparative pharmacology of josamycin and erythromycin stearate. Antimicrob Agents Chemother1976; 10: 450–6.
11.
HughesBRCunliffeWJ. Erythromycin and gastrointestinal motility (letter). Lancet1987; 2: 1340.
CodeCFMarlettJA. The interdigestive myoelectric complex of the stomach and small bowel of dogs. J Physiol1975; 246: 289–309.
14.
JenneweinHMHummeltHSiewertRWaldeckF. The motor stimulating effect of natural motilin on the lower esophageal sphincter, fundus, antrum and duodenum in dogs. Digestion1975; 13: 246–50.
15.
StrunzUDomschkeWMitzneggPDomschkeSSchubertEWiinschEAnalysis of the motor effects of 13-norleucine motilin on the rabbit, guinea pig, rat, and human alimentary tract in vitro. Gastroenterology1975; 68: 1485–91.
16.
ItohZNakayaMSuzukiTAraiHWakabayashiK. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol1984; 247: G686–94.
17.
TomomasaTKuroumeTAraiHWakabayashiKItohZ. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci1986; 31: 157–61.
18.
JanssensJPeetersTLVantrappenGTackJUrbainJLDe RooMImprovement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med1990; 322: 1028–31.
19.
UrbainJLCVantrappenGJanssensJVan CutsemEPeetersTDe RooM. Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids. J Nucl Med1990; 31: 1490–3.
20.
MozweczHPavelDPitrakDOrellanaPSchlesingerPKLaydenTJ. Erythromycin stearate as prokinetic agent in postvagotomy gastroparesis. Dig Dis Sci1990; 35: 902–5.
21.
EichenwaldHF. Adverse reactions to erythromycin. Pediatr Infect Dis1986; 5: 147–50.
22.
McLaranCJGershBJOsbornMJWoodDLSugrueDDHolmesDRIncreased vagal tone as an isolated finding in patients undergoing electrophysiological testing for recurrent syncope: Response to long term anticholinergic agents. Br Heart J1986; 55: 53–7.
23.
AlmquistAGoldenbergIFMilsteinSChenMYChenXHansenRProvocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med1989; 320: 346–51.
24.
GrahamDTKablerJDLunsfordLJrVasovagal fainting: A diphasic response. J Psychosom Res1961; 23: 493–507.
25.
GlickGYuPN. Hemodynamic changes during spontaneous vasovagal reactions. Am J Med1963; 34: 42–51.
26.
ChosyJJGrahamDT. Catecholamines in vasovagal fainting. J Psychosom Res1965; 9: 189–94.
27.
VingerhoetsAJJM. Biochemical changes in two subjects succumbing to syncope. Psychosom Med1984; 46: 95–103.
28.
AlmquistAGoldenbergIFBensonDWJrDunniganABendittDG. Provocation of bradycardia and hypotension by isoproterenol in patients with unexplained syncope (abstract). Circulation1986; 74 (suppl):II–32.
29.
WaxmanMBYaoLCameronDAWaldRWRosemanJ. Isoproterenol induction of vasodepressor-type reaction in vasodepressorprone persons. Am J Cardiol1989; 63: 58–65.
30.
GoldenbergIFAlmquistADunbarDNMilsteinSPritzkerMRBendittDG. Prevention of neurally mediated syncope by selective beta, adrenoreceptor blockade (abstract). Circulation1987; 76 (suppl):IV–133.
31.
GrubbBPTemesy-ArmosPHahnHElliottL. Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin. Am J Med1991; 90: 6–10.
32.
MilsteinSBuetikoferJDunniganABendittDGornickCReysW. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol1990; 65: 1339–44.
33.
MilsteinSBuetikoferJLesserJGornickCBendittD. Disopyramide reversal of induced hypotension bradycardia in neurally mediated syncope (abstract). Circulation1987; 76 (suppl):IV–175.
34.
IbrahimNMTaraziRCPustanHP. Orthostatic hypotension: Mechanisms and management. Am Heart J1975; 90: 513–9.
35.
CalkinsHKadishASousaJRosenheckSMoradyF. Comparison of responses to isoproterenol and epinephrine during head-up tilt in suspected vasodepressor syncope. Am J Cardiol1991; 67: 207–9.
36.
SraJSAndersonAJSheikhSHAvitallBTchouPJTroupPJUnexplained syncope evaluated by electrophysiologic studies and head-up tilt testing. Ann Intern Med1991; 114: 1013–9.
37.
KapoorWNKarpfMWieandSPetersonJRLeveyGS. A prospective evaluation and follow-up of patients with syncope. N Engl J Med1983; 309: 197–204.
38.
WeisslerAMLeonardJJWarrenJV. The hemodynamic effects of isoproterenol in man. J Lab Clin Med1959; 53: 921–5.
